EBD GmbH is part of the KNect365 of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
 
BIO-Europe Spring EBD Group BIO BIO-Europe Spring
Share/Follow Us
Share this:
Follow this event:

BIO-Europe Spring® Program Overview

www.ebdgroup.com/bes/program
Sunday, April 3, 2016
19:00–21:30
Welcome Reception

All BIO-Europe Spring attendees are cordially invited to join us for a welcome reception.

You will be able to pick up your name badge at the welcome reception.

Berns Stora Salongen

Berns Stora Salongen
Berzelii Park
10327 Stockholm
Sweden | (map)

Since its doors opened in 1863, Berns has been an oasis for curious cosmopolitans. It is a concert venue, hotel, restaurant and nightclub in the heart of Stockholm where celebrities mix with up-and-coming artists, businessmen and media people.

The astonishing Stora Salongen (Great Salon) was Stockholm's first concert hall and the center of cabaret in the 1880s. With its fine gold and plaster molding, magnificent crystal chandeliers and a twelve-meter-high ceiling, it has always provided a beautiful yet intimate setting for new as well as world-famous artists such as Diana Ross & The Supremes, Bob Dylan and Rihanna.

Monday, April 4, 2016
07:45
Level 0, Foyer
Registration opens
07:45
Level 1, Hall 2 (Exhibit)
Exhibition opens and Continental Breakfast
09:00–10:30
Parallel Workshops
New partnerships are a sign of the times: Opportunities for collaborations

Monday, 09:00–10:30
Level 0, Room E4

Now more than ever before, we are seeing cross-sector collaborations that are changing traditional R&D models. Whether they're public-private partnerships, patient foundations and biotechs, incubators and pharmacos, or government entities and industry, novel agreements between stakeholders are leveraging the assets and expertise available to make greater progress and contributions to science. We'll review some prime examples of successful and impactful partnerships.

Moderator:
Mike Ward – Global Director of Content, Informa Pharma Insights

Panelists:
  • J. Alan Butcher – Head, Licensing and Business Development, Purdue Pharma LP
  • Hilary Hehman – Director of Strategic Partnerships, Cincinnati Children's Hospital
  • Sarah Holland – Head of Europe, External Science and Partnering, Sanofi
  • Issi Rozen – Chief Business Officer, Broad Institute
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
Finding the sweet spot: Defining and accessing your market

Monday, 09:00–10:30
Level 0, Room E5

In the push to prove a successful end point, biotech companies can often lose sight of the more practical hurdles that also exist in getting their products on the market. Moving a therapy out of the lab and into the commercial arena raises questions of how to operate in a complex policy and legal landscape, including patents and IP, regulatory regimes and reimbursement and healthcare systems. Early market access activities and partnerships can mitigate or increase risk, but are complicated by the need to manage these hurdles in multiple jurisdictions. What effective strategies can assist in identifying these hurdles in order to position new drugs, not just as therapies but as products with a secure pathway to an end user? How must the partnering approach market access planning shift in order to take the full spectrum of drug development, clinical, legal and commercial, into account?

Moderator:
Joseph Damond – Senior VP, International Affairs, Biotechnology Innovation Organization (BIO)

Panelists:
  • Jeremy Broadis – VP, European Market Entry, Quintiles
  • Barbara Freischem – Executive Director, EBE
  • Niklas Mattsson – Partner and European Patent Attorney, Awapatent
  • Bernd Mühlenweg – Chief Business Officer, Nanobiotix
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
Let's get personal: Advances in precision medicine are changing the way we identify and treat disease

Monday, 09:00–10:30
Level 0, Room E6/7

It's no longer "one Rx fits all"—with the ability to identify biomarkers, development of advanced diagnostics, and funding for projects like GRAIL, the age of precision medicine is here. We'll hear how patient data is being used with new technologies to develop targeted therapies that are impacting the way we are not only diagnosing diseases but the way we are treating them.

Moderator:
Thomas Wilckens – CEO, InnVentis Ltd.

Panelists:
  • Steve Ford – Chief Executive, Parkinson's UK
  • Tero Silvola – CEO, BC Platforms
  • Laura Vidal – Medical Director, Oncology, INC Research
  • Urs Wiedemann – VP, Charles River Associates
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
The future of vaccine development

Monday, 09:00–10:30
Level 0, Room E8

Strategic alliances are necessary to insure a balance of commercial viability while providing access to diverse patient populations. How are companies, research organizations, government agencies, and others working together to overcome the challenges of innovation, development, manufacturing, and market access? Panelists will discuss the unique economic and societal considerations in addressing infectious diseases.

Moderator:
Cornelius Schmaltz – Head of Unit, Directorate Health, European Commission

Panelists:
  • Olivier Adam – Director, External R&D, Sanofi
  • Sven Andréasson – Senior VP, Corporate Development, Novavax, Inc.
  • Marie-Liesse Le Corfec – Senior Director, Head of Global Strategic Marketing, Vaccine Business Unit, Takeda Pharmaceuticals
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
10:00–18:30
One-to-one Meetings ►
10:45–12:30
Level 1, Hall 1, Room M1/M2
Welcome and Plenary Session
Welcome
Opening remarks

Monday, 10:45–11:15
Level 1, Hall 1, Room M1/M2

Speakers:
  • Anna Chrisman – Group Managing Director, EBD Group
  • Karin Wanngård – Mayor of Stockholm
  • Helene Hellmark Knutsson – Minister for Higher Education and Research, Sweden
  • David Thomas – Senior Director, Industry Research and Analysis, Biotechnology Innovation Organization (BIO)
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
Opening Plenary Session
Environment in 2016: Reverse engineering the ecosystem

Monday, 11:15–12:30
Level 1, Hall 1, Room M1/M2

Moderator:
Denise Scots-Knight – CEO and Founder, Mereo BioPharma Group Ltd

Panelists:
  • Shaun Grady – VP, Business Development Operations, AstraZeneca
  • Jan M. Lundberg – Executive VP, Science and Technology and President, Lilly Research Laboratories, Eli Lilly and Company
  • Richard Mason – Head, Johnson & Johnson Innovation, London
  • Bernd R. Seizinger – Executive Chairman, Aprea AB
  • Christian Zahnd – CEO, Molecular Partners AG
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
Moderator:
Denise Scots-Knight Denise Scots-Knight
CEO and Founder
Mereo BioPharma Group Ltd

Speakers:
Shaun Grady Jan M. Lundberg Richard Mason Bernd Seizinger
Shaun Grady
VP,
Business Development Operations
AstraZeneca
Jan M. Lundberg
Executive VP,
Science and Technology and President
Lilly Research Laboratories
Eli Lilly and Company
Richard Mason
Head,
Johnson & Johnson Innovation
London
Bernd R. Seizinger
Executive Chairman,
Aprea AB
Christian Zahnd
Christian Zahnd
CEO,
Molecular Partners AG
12:00–14:00
Level 1, Hall 1, Room M1/M2
Level 1, Hall 2 (Exhibit) and Foyer
Luncheon
13:30–18:15
Parallel Panel Discussions
Business Development
Keeping your head: VCs and biotechs navigating uncertain markets

Monday, 13:30–14:30
Level 0, Room E8

After a period of strong growth, healthcare has not proved immune to the volatility of the financial markets early this year. VCs, usually the first port of call for fundraising biotechs, have an important role to play in ensuring innovation continues but are still vulnerable to the vagarities of market cycles. How do VCs differentiate themselves when capital is plenitful? How can they foster growth and innovation when slowdowns render risk unpalatable? Can VCs operate so as to drive sustainable healthcare market growth rather than a new bubble or a new trough?

Moderator:
Adrian Dawkes – VP, PharmaVentures

Panelists:
  • Michele Ollier – Co-Founder, Medicxi Ventures
  • Stuart Collinson – Partner, Forward Ventures
  • Adam Kostyál – Senior VP, Global Listing Services, EMEA, Nasdaq
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
The Alliance Manager: Bridging the culture gap

Monday, 14:45–15:45
Level 0, Room E8

Drug development has never been more collaborative. Companies big and small, disease foundations, university research departments, government health services, and more are all potential partners for the development of new therapeutics. The sheer variety of organizations working together can result in the collision of differing organizational cultures and it is at this juncture that the role of alliance manager comes into its own. Join this panel to hear recent examples of how alliance managers translate the processes, languages, and structures between companies to ensure that, to achieve the end goal of every partnership, the entire team is following the same playbook.

Moderator:
Mark Archer – Global Head, Business Development, inVentiv Health

Panelists:
  • Josep M. Casanovas – Head of Immuno-Dermatology External Innovation and Licensing, Corporate Development, Almirall
  • Igor Fisch – CEO, Selexis
  • Mark Rowen – Associate Director, Business Development, Genentech Partnering
  • Steven Twait – VP, Alliance and Integration Management, AstraZeneca
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
The new normal: Effective alternative financing

Monday, 16:00–17:00
Level 0, Room E8

As demands on healthcare systems around the world shift in response to demographic changes and the burden of growing chronic conditions, there is a growing need for newer sources of capital to add to the traditional ones to fund the development of therapies. As a result, the financial aspect of healthcare is seeing a new breed of participants who are eager to establish themselves as long-term contributors. Disease foundations led by private donors, organizations created to support initiatives that answer the needs of specific patient populations, wealthy individuals keen to contribute to achievable if ambitious healthcare targets; these and others are all claiming their place on the spectrum of healthcare financing. Join this panel to hear from funders, companies and organizations who are actively engaged in the new matrix of alternative healthcare finance. Learn how you can engage with these new players and make the most of the expanding variety of options in your industry.

Moderator:
Steve Dickman – CEO, CBT Advisors

Panelists:
  • Charlotte Brogren – Director General, Vinnova
  • Christopher De Souza – Director, Broadview Ventures
  • Viktor Drvota – Chief Investment Officer, Karolinska Development
  • Ailis Tweed-Kent – CEO and Founder, Cocoon Biotech
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
The convergence of therapeutics and digital health.

Monday, 17:15–18:15
Level 0, Room E8

Digital health is evolving rapidly with the development of products that have medical applications. Gain insight on big pharma's approach to these emerging digital medicine technologies including the unique partnership opportunities and strategies. Panelists will discuss how therapeutic applications, clinical trials, drug delivery, and adherence will be altered by digital medicine's influence.

Moderator:
Erika Rask – Sales Manager, MedUniverse

Panelists:
  • Karolina Antonov – Head of Strategy, LIF, Swedish Pharmaceutical Association
  • Mats Berggren – Health Policy and Market Access, Merck
  • Theresia Bredenwell – External Affairs Director, AbbVie
  • Nima Jokilaakso – Executive Partner, D Health Scandinavia
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
Partnerships in Cell and Gene Therapies


Partnerships in Cell and Gene Therapies
Cell therapies: The panacea for all that ails us

Cell therapies: The panacea for all that ails us
Monday, 13:30–14:30
Level 0, Room E5

We have seen exciting advances in this field but what will it take to bring cures to the market? The emergence of new technologies to potentially treat neurological, immunological, and genetic diseases is promising but there are many pitfalls. This session will discuss the clinical, manufacturing, and regulatory pathways towards realizing the promise of these therapies.

Moderator:
Phil Vanek – GM, Cell Therapy Technologies, GE Healthcare

Panelists:
  • Thomas Liénard – Chief Business Officer, Bone Therapeutics SA
  • Miguel Mulet – Director, Strategy and New Projects, TiGenix NV
  • Georges Rawadi – VP, Business Development, Celyad
  • Jeff Till – Director, External Innovation, Merck
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
Targeted cancer therapies: Breakthroughs in new treatments

Targeted cancer therapies: Breakthroughs in new treatments
Monday, 14:45–15:45
Level 0, Room E5

With the advances in immunotherapies, we have seen more partnerships, IPOs, and clinical developments than ever before. Whether through checkpoint inhibitors, combination therapies, or CAR-T therapies, there is much to be excited about. We will highlight the newest breakthroughs and explore what's in the pipeline that has the industry buzzing.

Moderator:
Mike Ward – Global Director of Content, Informa Pharma Insights

Panelists:
  • Iain Dukes – Senior VP, Business Development and Licensing, MSD
  • Kevin Foote – Director External Projects, iMed Oncology, AstraZeneca
  • Philippe Lopes-Fernandes – Senior VP, Head, Global Business Development and Alliance Management, Merck
  • Olav Zilian – Senior VP, Corporate Development, Medigene AG
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
Advanced therapies: The keys to treating rare diseases

Advanced therapies: The keys to treating rare diseases
Monday, 16:00–17:00
Level 0, Room E5

In treating Duchenne Muscular Dystrophy, Huntington's disease, cystic fibrosis, and other rare diseases, we are seeing new technologies transforming the treatment landscape. Hear from the leading companies as they discuss the promising advances that may not only treat but possibly cure these rare disorders.

Moderator:
David Greenwald – Director, Business Development, Johns Hopkins Technology Ventures

Panelists:
  • Jaap de Boer – Director, Scientific Development and Alliance Management, Business Operations Europe, Sanofi Genzyme
  • Stephen James – VP, Head of Research and Drug Design and Development, Swedish Orphan Biovitrum AB (Sobi)
  • Christian Meyer – Chief Medical Officer, UniQure
  • Yael Weiss – Executive Director, Business Development, Ultragenyx Pharmaceutical
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
It's not a mirage: The promise of cell and gene therapy is real

It's not a mirage: The promise of cell and gene therapy is real
Monday, 17:15–18:15
Level 0, Room E5

How will the landscape change as more diseases have the potential to be treated or even cured with the advances in this field? What will it take to make these promises into a reality? Pharma execs will share insights on their strategies in developing, manufacturing, and commercializing these life-changing treatments.

Moderator:
Morrie Ruffin – Managing Partner, Adjuvant Partners

Panelists:
  • Vered Caplan – CEO, Orgenesis
  • John McDonald – VP, Business Development, Biogen
  • Alexandra Richardson – Head, Business Development, Clayton Biotechnologies, Inc.
  • Jason Slingsby – Head, Business Development, Oxford BioMedica
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
Therapeutic Insight 2016


Therapeutic Insight by Defined Health
Connecting drug pricing to value: The industry's greatest challenge

Connecting drug pricing to value: The industry's greatest challenge
Monday, 13:30–14:30
Level 0, Room E6/7

The drug pricing controversy now raging in the US has only one solution that will be palatable to the healthcare industry complex; there is nearly universal agreement that the price of drugs must be firmly based on their value. Indeed, unless this is done, we run the risk of killing the fruits of the enormous scientific progress made over the past 10 years. But espousing this objective is a lot simpler than accomplishing it, as value is very much in the eyes of the beholden stakeholder. In the EU, where value based pricing is the norm, the stakeholder vote is controlled almost entirely by the payer, and is based on long-established but nonetheless quite crude metrics (such as DALY). And in the US, where both the costs and benefits of drugs can impact a number of different key stakeholders over time, hurdles to demonstrating value are even more daunting.

This panel will discuss the numerous obstacles that exist to consistently and objectively valuing prescription medicines and explore innovative ways in which these can be addressed.

Moderator:
Ed Saltzman – President, Defined Health

Panelists:
  • Joseph Damond – Senior VP, International Affairs, Biotechnology Innovation Organization (BIO)
  • Paul K. Gallagher – President, Compass Strategic Consulting, Inc.
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
Management of diabetes: Beyond the insulin and incretin pathways

Management of diabetes: Beyond the insulin and incretin pathways
Monday, 14:45–15:45
Level 0, Room E6/7

Large Pharma Diabetes franchises (Novo Nordisk, Sanofi, Merck, and Eli Lilly), driven by innovative insulins and incretin pathway modulators (GLP-1 and DPPIV), have experienced rapid growth in recent years. The newest drug class in the treatment of type 2 diabetes, SGLT-2 inhibitors (gliflozins), was originally pursued after gene mutations in SGLT-2 were found in people with a benign familial renal glucosuria. Inhibition of SGLT-2 blocks reabsorption of glucose in the kidney and represents the first insulin-independent glucose lowering agent that not only lowers HbA1c, but has a favorable body weight reduction profile and has shown cardiovascular outcomes improvement when added to standard of care. However, when one looks at the antidiabetic drug development pipeline today, there is a concern that such innovation is lacking and that, despite the growing magnitude of the disease prevalence, with genericization of the category and the advent of biosimilars, the diabetes market growth trajectory may be coming to an end. In an attempt to stimulate innovation and address currently underserved patient populations, there is interest in studying micro-specialty, metabolic diseases and adding novel modes of therapy into development portfolios. In this context, the panel will discuss emerging science leading to treatments for such special populations (neonatal diabetes, hyperinsulinemia, and Maturity Onset Diabetes of the Young (MODY)), and evaluating the potential of RNA-based therapies (PTP-1B, PCSK9, ApoC-III, APO(a), etc.) and gene and cell based therapies (Gene Editing, Regulatory T-Cell and artificial pancreases).

Moderator:
Michael C. Rice – Senior Consultant, Defined Health

Panelists:
  • Cord Dohrmann – Chief Scientific Officer and Member of the Management Board, Evotec
  • Olle Korsgren – Professor, Cell Therapeutics, Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University Hospital
  • Tomas Landh – Innovation Sourcing VP, Senior Principal Scientist, Novo Nordisk
  • Matthias Urmann – Associate VP, Diabetes External Innovation, Sanofi
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
After inflammation, fibrosis: Will biopharma follow nature's lead?

After inflammation, fibrosis: Will biopharma follow nature's lead?
Monday, 16:00–17:00
Level 0, Room E6/7

The autoimmune inflammatory disease (AIID) category is one of the largest in the pharmaceutical industry responsible for >USD 50 billion in sales/year. Success in this category was driven by development of therapeutics targeting conserved mediators (e.g. TNFα) that contribute to a large variety of AIIDs. Although pharma continues to profit from AIID, a number of observations suggest that innovators may soon need to look elsewhere: (1) key indications driving sales are well-served by available products; (2) existing franchises now cover many of the remaining indications; (3) payers are pushing back on products that don't provide superior outcomes; (4) biosimilars are coming! Like AIID, fibrosis represents a common process driven by conserved mediators, but fibrosis remains an area of great unmet need and untapped commercial potential (e.g., sales for NASH may reach USD 35-40 billion by 2025). As fibrosis is often the end-result of inflammation, companies developing AIID drugs may be well positioned to capitalize on the enormous potential of this space. However, fibrosis poses its own unique set of challenges (e.g., prevention vs. treatment paradigm, lack of non-invasive biomarkers, unclear regulatory path, potential for payer pushback). This panel will discuss the potential and pitfalls of looking beyond AIID to the uncharted territory of fibrosis.

Moderator:
David J. Lomb – Senior Consultant, Defined Health

Panelists:
  • Matthias Corbascio – VP, Inflammation, IsletOne Therapeutics
  • Donnie McGrath – VP, Search and Evaluation, Business Development, Bristol-Myers Squibb
  • Elias Papatheodorou – CEO, Genkyotex SA
  • Hans T. Schambye – CEO, Galecto Biotech AB
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
Neurodegenerative disorders: Are we finally scaling the wall?

Neurodegenerative disorders:  Are we finally scaling the wall?
Monday, 17:15–18:15
Level 0, Room E6/7

There have been several notable company formation/financing announcements in the field of neurodegenerative disease of late (Denali, Voyager, Yumanity), coming off of years of little investment in the field. The increased willingness on the part of investors and pharma to jump in now is due to a convergence of factors, including advances in the science, better understanding of disease due in part to the development of better imaging and other tools, and improved animal and disease models. In parallel, we have seen vastly improved access to funding, reflecting the increase in investor enthusiasm due to perceived risk reduction more in line with investor risk tolerance, and reinforced by the sustained availability of an open IPO window.

The tremendous unmet need in neurodegenerative conditions remains unchanged. What remains to be done to move the needle sufficiently in terms of our understanding of disease biology, validated targets, disease models, and biomarkers in order to move the field markedly forward?

Moderator:
Ginger S. Johnson – VP, Defined Health

Panelists:
  • Anders Hinsby – CEO, Orphazyme ApS
  • Christer Nordstedt – VP, Neuroscience Discovery Research and Clinical Investigation, Eli Lilly and Company
  • Per Svenningsson – Professor, Department of Clinical Neuroscience, Karolinska Institutet
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
Pharma Presentations
AZ BioVentureHub

AZ BioVentureHub
Monday, 13:45–14:00
Level 0, Room E4

Speaker:
  • Magnus R. Björsne – CEO, AZ BioVentureHub
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
14:00–14:15
Sanofi

Sanofi
Monday, 14:00–14:15
Level 0, Room E4

Speaker:
  • Sarah Holland – Head of Europe, External Science and Partnering
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
Eli Lilly and Company

Eli Lilly and Company
Monday, 14:15–14:30
Level 0, Room E4

Speaker:
  • Johnston Erwin – VP, Strategy and Operations
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
Johnson & Johnson

Johnson & Johnson
Monday, 14:30–14:45
Level 0, Room E4

Speaker:
  • Richard Mason – Head, Johnson & Johnson Innovation, London
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
14:45–15:00
Amgen

Amgen
Monday, 14:45–15:00
Level 0, Room E4

Speaker:
  • Ray Barlow – Executive Director
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
15:00–15:15
AbbVie

AbbVie
Monday, 15:00–15:15
Level 0, Room E4

Speaker:
  • Murali Gopalakrishnan – Senior Director, Head, Search and Evaluation Neuroscience
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
15:15–15:30
Roche

Roche
Monday, 15:15–15:30
Level 0, Room E4

Speaker:
  • Enza Di Modugno – Director: Global Business Development, Roche Partnering Infectious Diseases, Inflammation, Specialty Care
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
15:30–15:45
Genentech

Genentech
Monday, 15:30–15:45
Level 0, Room E4

Speaker:
  • Jacqueline Grant – Manager, Genentech Partnering
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
15:45–16:00
Novartis

Novartis
Monday, 15:45–16:00
Level 0, Room E4

Speaker:
  • Charles Bailey – Global Head, Search and Evaluation, Neurosciences
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
16:00–16:15
Merck

Merck
Monday, 16:00–16:15
Level 0, Room E4

Speaker:
  • Philippe Lopes-Fernandes – Senior VP and Head, Global Business Development and Alliance Management
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
16:15–16:30
Novo Nordisk

Novo Nordisk
Monday, 16:15–16:30
Level 0, Room E4

Speaker:
  • Tomas Landh – Innovation Sourcing VP, Senior Principal Scientist, Novo Nordisk
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
16:30–16:45
Pfizer

Pfizer
Monday, 16:30–16:45
Level 0, Room E4

Speakers:
  • Ron Newbold – VP, Global Scouting; External R&D Innovation
  • James Eshelby – Senior Director, R&D Business Development
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
16:45–17:00
MSD

MSD
Monday, 16:45–17:00
Level 0, Room E4

Speaker:
  • Reza Halse – Head, European BD&L Innovation Hub
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
Takeda Pharmaceuticals Company Ltd.

Takeda Pharmaceuticals Company Ltd.
Monday, 17:00–17:15
Level 0, Room E4

 

BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
17:15–17:30
Bayer

Bayer
Monday, 17:15–17:30
Level 0, Room E4

Speaker:
  • Martin Beuck – Head of Operations, Business Development and Licensing
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
Bristol-Myers Squibb

Bristol-Myers Squibb
Monday, 17:30–17:45
Level 0, Room E4

Speaker:
  • Donnie McGrath – VP, Search and Evaluation, Business Development
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
17:45–18:00
Purdue Pharma

Purdue Pharma
Monday, 17:45–18:00
Level 0, Room E4

Speaker:
  • Kathryn Gregory – Executive Director, Licensing and Business Development
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
18:00–18:30
Level 1, Hall 2, Booth 14
Champagne reception at EBD Group booth
19:00–21:00
Evening Networking Reception
Stockholm City Hall

Stockholm City Hall
Hantverkargatan 1
Entrance: through Inner Courtyard
11152 Stockholm | (map)

The City of Stockholm and the Stockholm County Council invite you to a networking reception in the amazing Blue and Golden Halls.

The Stockholm City Hall is one of Sweden’s most famous buildings, and one of the capital's most visited tourist attractions. It houses offices for 200 people including the Municipal Council, and is also famous for its grand ceremonial halls and unique art pieces, like the Golden Hall with its more than 18 million pieces of gold mosaic. The Stockholm City Hall is the venue of the Nobel Prize banquet held on December 10 each year.

The reception will end at 21:00.

Sponsored by:

Stockholm, capital of Scandinavia Stockholm, capital of Scandinavia

18:15–18:45 Shuttle buses depart from the conference center to the evening event.
20:45–21:45 Shuttle buses depart from the evening event to all conference hotels.

Tuesday, April 5, 2016
07:45
Level 0, Foyer
Registration opens
07:45
Level 1, Hall 2 (Exhibit)
Exhibition opens and Continental Breakfast
09:00–10:00
Panel Discussion
Innovation in early stage funding

Tuesday, 09:00–10:00
Level 0, Room E4

Research institutes active in life sciences face the "gap funding issue" of highly risky opportunities and look for seed funding solutions for their development into patient solutions. Therefore, academic institutes as well as pharma and venture capital companies in Europe are experimenting new ways to fuel and progress academic projects into the market arena, as this will create the critical mass of deal flows on which the European biotech industry can build. In this session, we link the different perspectives from all players involved.

Moderator:
Jan Staelens – Business Development Manager, VIB

Panelists:
  • Magnus R. Björsne – CEO, AZ BioVentureHub
  • Peter Nordström – Program Director, SWElife
  • Graziano Seghezzi – Partner, Sofinnova Partners
  • Alexander von Gabain – Deputy Vice-Chancellor, Innovation and Commercial Outreach, Karolinska Institutet
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
08:00–18:30
One-to-one Meetings ►
09:00–12:00
Company Presentations ►
10:15–11:45
Workshop
Innovative funding for SMEs in Europe

Innovative funding for SMEs in Europe
Tuesday, 10:15–11:45
Level 0, Room E4

How do I, an innovative, ambitious SME, succeed in accessing EU funds in the field of health research? The answer is given during this session not only by policy makers, but also by a concrete success story of a company which was listed on the stock exchange after receiving the necessary boost from one of the European Union's specialized financing facilities.

Stimulating breakthrough innovation, the SME instrument—a EUR 3 billion funding program dedicated to innovative Small and Medium-sized Enterprises (SMEs) in Europe as part of Horizon 2020—may offer an individual SME up to EUR 5 million. The session will provide an overview of this program and will also introduce other Horizon 2020 SME-oriented facilities such as InnovFin - EU Finance for Innovators, co-developed with the European Investment Bank (EIB).

For a dynamic discussion, we will bring together representatives from the European Commission, the Innovative Medicines Initiative (the world's largest public-private partnership in the area of health research) and the EIB. In addition, a European small business will share its experience in leveraging government funding as well as venture capital to move their technology towards commercialization.

Moderator:
Cornelius Schmaltz – Head of Unit, Directorate Health, European Commission

Speakers:
  • Mats Grahn – CEO, Immunovia
  • Homan Panahi – CEO, Vator Securities AB
  • Constantinos Ziogas – Head of Small and Medium-Sized Enterprise Office, European Medicines Agency (EMA)
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
12:00–13:00
Panel Discussion
Opportunities for cross-border partnering and fundraising in China

Tuesday, 12:00–13:00
Level 0, Room E4

China is now the second largest pharma market after the US and is on track to become the largest market by 2020. Chinese companies are actively seeking drug candidates and products from European companies to bring to China, with total deal value more than doubling last year to over USD 4.2 billion. Venture capital and corporate funding of life science companies is also exploding in China, exceeding USD 6 billion in 2015. This special session will explore what it takes to secure partners and funding in China, with senior executives who have all done multiple cross-border deals, including the largest licensing deal to date, valued at over USD 1 billion.

Moderator:
Robert Narquizian – VP International Business Development, ChinaBio® Group

Panelists:
  • Sammy Jiang – VP, Strategy Planning and Business Development, Luye Pharma
  • H. Michael Keyoung – President and CEO, Genexine
  • Xueming Qian – Chairman and CEO, MabSpace BioSciences
  • Dan Zhang – Founder, Chairman and CEO, Fountain Medical Development Ltd.
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
12:00–14:00
Level 1, Hall 1, Room M1/M2
Level 1, Hall 2 (Exhibit) and Foyer
Luncheon
14:00–15:30
Workshop
Phase I: An inflection point in drug development and value generation

Phase I: An inflection point in drug development and value generationPhase I: An inflection point in drug development and value generation
Tuesday, 14:00–15:30
Level 0, Room E4

An increasing number of "open innovation" initiatives aim to bring novel therapeutics to patients faster by facilitating public private partnerships, to solve common challenges encountered during the discovery and the drug development process.

Disruptive anticancer therapies increasingly come from small startups and biotechs. Phase I units in academic institutions have an active role to advance these innovations into the clinic. Biotech companies benefit from collaborating with Phase I experts well before Phase I trials will be initiated. Accessing this clinical expertise early on can significantly accelerate the development of disruptive innovations and increase the chance of success. Global pharmaceutical companies and investors play a major role in advancing novel therapies to patients. They partner both with biotechs as well as with academic centers, contributing their expertise in drug development and financial support.

In the first part of the session flagship academic institutions in Europe will show how they play the game, and how they can support small biotech companies in their drug development efforts. In the second part executives from biotech, pharma and the investment side will discuss the relevance and added value generated via Phase I clinical development and illustrate with case studies and examples for win-win partnerships.

Speakers:
  • Jean-Pierre Armand – Senior Oncologist, Expert in Phase I/II, Gustave Roussy Institute
  • Jeffrey Yachnin – Clinical Trials Unit, Department of Oncology, Karolinska University Hospital

Moderator:
Mark Nuttall – VP, Business Development and Licensing, Neuroscience, Janssen Business Development

Panelists:
  • Martin Bonde – CEO, Vaccibody
  • Johan Christenson – Partner, HealthCap
  • Dominique Costantini – CEO, OSE Pharma
  • Loïc Vincent – Head, Oncology External Innovation, Sanofi
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
14:00–18:00
Company Presentations ►
14:30–15:30
Level 1, Hall 2, Booth 66
Stockholm Hour

Join our Swedish Host Sponsor and learn more about investments opportunities in the region.

Hosted by:

Stockholm Stockholm
15:30–18:00
Start-up slam: Sweden
Start-up slam: Sweden

Tuesday, 15:30–18:00
Level 0, Room E8
#StartupSlam16

Sponsored by:

J&J Innovation J&J Innovation Karolinska Institutet Innovations

Co-sponsored by Karolinska Institutet Innovations and Johnson & Johnson Innovation, this special program will feature presentations from 18 of the best and the brightest from Sweden's early academic innovator ecosystem.

Moderators:
Lily C. Cortese – Director, Strategy and Business Operations, Johnson & Johnson Innovation, London Innovation Centre
Mark Farmery – Senior Manager, Business Development, Karolinska Institutet Innovations AB

Judges:
  • Anders Ekblom – Director of the Board, Swedish Research Council; Chairman of the Board, Karolinska University Hospital and TFS International AB
  • Declan Jones – VP, Neuroscience Lead, Johnson & Johnson Innovation, London Innovation Centre
  • Nina Rawal – Investment Director, Head of Business Unit Life Science, Industrifonden

Participating companies:

Session 1: Targeted therapeutics
AlziNova
Emeriti Pharma AB
PILA Pharma AB
Sixera Pharma AB
BTB Pharma AB
Helleday Laboratory
AlzeCure
Apoglyx AB
LipUm AB

Session 2: Platform technologies, diagnostics and devices
Single Technologies
ExScale Biospecimen Solutions AB
MediTuner
UtiGel
NeoProteomics
iCellate Medical AB
Biotherapeutics
QureTech Bio
ImmuneBiotech AB

15:30 Welcome and introduction to Judging Panel
15:45 Pitching set 1
16:40 Pitching set 2
17:25 Networking with pitching companies
17:45 Winner announced

Johnson & Johnson Innovation is sponsoring an entrepreneurs and startups pitching competition at BIO-Europe Spring 2016. A panel of judges, which will include representatives of Johnson & Johnson Innovation, will choose a winner from among 18 pre-selected applicants that met specific eligibility requirements. Participants will be expected to deliver a three-minute pitch of their business plan. The winner of this competition will receive a EUR 5,000 grant from Johnson & Johnson Innovation towards his/her research and a complimentary presentation slot and one full access registration to the 2016 BIO-Europe event.

BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
#StartupSlam16

Sponsored by:

J&J Innovation J&J Innovation Karolinska Institutet Innovations
15:45–16:45
Panel discussion
How could life science industry capitalize on a life science cluster?

Tuesday, 15:45–16:45
Level 0, Room E4

How can your organization benefit from being present in a life science cluster? We still are in an era of consolidation in the life science industry with a large number of mergers and acquisitions, and a redistribution of R&D resources towards external activities and collaborations. In addition, there is increasing competition from the emerging markets globally combined with the challenge of rising healthcare costs. As a result the small and medium sized enterprises (SMEs) as well as universities are important as additional drivers for continued innovation and growth. How can you take advantage of external research capabilities and strong regional networks? In this session our panelists will share their views and different perspectives on how to derive the most benefit from life science clusters.

Moderator:
Jenni Nordborg – Director and Head, Health Division, Vinnova

Panelists:
  • Jan Andersson – Director, Research and Innovation, Stockholm County Council
  • Kurt Hertogs – Platform Innovation and Incubator Strategy Leader, Johnson & Johnson Innovation Center
  • Ulf Janzon – Policy and Communications Director, MSD Sweden
  • David Johansson – Chairman of the Board, Hagastaden Property Developers
  • Mary Lindenstein Walshok – Associate Vice Chancellor for Public Programs and Dean of Extension, University of California San Diego
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
17:45–18:45
Level 1, Hall 2
Exhibit Hall Hospitality Receptions
ASEBIO ASEBIO
at Booth 63A
Health - Holland Health - Holland
at Booth 60
Informa Pharma Intelligence Informa Pharma Intelligence
at Booth 47
19:00–24:00
Evening Networking Reception
Karolinska Institutet

© Photographer: Ulf Sirborn

Karolinska Institutet
Aula Medica
Nobels väg 6
171 65 Solna, Sweden | (map)

Our evening event sponsors Hagastaden Property Developers, Stockholm Science City and Karolinska Institute invite you to a typical Swedish Style Dinner and Networking Reception, followed by a Johnson & Johnson Innovation After Hours Making the Connection Networking Reception.

Karolinska Institutet is one of the world's leading medical universities and accounts for over 40 per cent of the medical academic research conducted in Sweden. Founded over 200 years ago, it has since 1901 selected the Nobel laureates in Physiology or Medicine. Karolinska Institutet's beautiful center, Aula Medica, boasts an auditorium with 1,000 seats, offices for about 100 people, 100 conference places, two restaurants and a cafe. Nobel lectures are arranged here, as well as scientific symposia, academic ceremonies and conferences.

Dinner Reception Sponsored by:

Hagestaden Hagestaden

After Hours Making the Connection Networking Reception Sponsored by:

J&J Innovation J&J Innovation

18:30–19:00 Shuttle buses depart from the conference center to the evening event.
21:15–24:00 Shuttle buses depart from the evening event to all conference hotels.

Wednesday, April 6, 2016
07:45
Level 0, Foyer
Registration opens
07:45
Level 1, Hall 2 (Exhibit)
Exhibition opens and Continental Breakfast
09:00–12:00
Company Presentations ►
08:00–17:00
One-to-one Meetings ►
11:00–12:00
Executive Discussion
Medicxi Ventures, GSK and J&J: Is the VC/pharma collaborative model working?

Wednesday, 11:00–12:00
Level 0, Room E4

Moderator:
Eric Pierce – Publisher, BioCentury

Panelists:
  • Kevin Johnson – Co-Founder and Partner, Medicxi Ventures
  • Luigi La Corte – Senior VP Finance and Head of Global Business Development, GlaxoSmithKline Pharma R&D
  • Johan Verbeeck – Head, External Partnering Strategy, Johnson & Johnson Innovation, Janssen Business Development
BIO-Europe Spring® 2016
Share this:Email this pageShare this on LinkedInShare this on Twitter
Moderator:
Eric Pierce Eric Pierce
Publisher,
BioCentury

Speakers:
Kevin Johnson Luigi La Corte Johan Verbeeck
Kevin Johnson
Co-Founder and Partner,
Medicxi Ventures
Luigi La Corte
Senior VP
Finance and Head
of Global Business Development,
GlaxoSmithKline Pharma R&D
Johan Verbeeck
Head,
External Partnering Strategy,
Johnson & Johnson Innovation,
Janssen Business Development
12:00–14:00
Level 1, Hall 1, Room M1/M2
Level 1, Hall 2 (Exhibit) and Foyer
Luncheon
16:30
Level 1, Hall 2 (Exhibit), Booth 35
Closing Reception

Sponsored by:

Biocat Biocat

Arrow Up

Follow this event:
Sign up now
For news and updates

Privacy Policy and Cookies Terms of Use

Home | Contact Us | Site Map
See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2016 EBD GmbH
Privacy Policy and Cookies
Terms of Use